A Statistical Miss in Rare Disease Research
The Phase 3 HICKORY clinical trial, evaluating AstraZeneca’s investigational enzyme replacement therapy efzimfotase alfa for hypophosphatasia (HPP), failed to meet its primary endpoint in March 2026. While patients treated with the drug demonstrated a 17.05-meter improvement in the Six-Minute Walk Test (6MWT) after 25 weeks, this result did not achieve statistical significance compared to the placebo group, which performed better than initial models had predicted, according to Clinical Trials Arena.
AstraZeneca, through its rare disease unit Alexion Pharmaceuticals, noted that while the primary endpoint was not reached, a post-hoc analysis indicated that 45.2% of patients treated with efzimfotase alfa achieved a minimum clinically important difference (MCID) in the 6MWT, compared to roughly 18% in the placebo arm. Despite these signals of efficacy and reported improvements in patient fatigue, the trial is widely viewed by industry observers as a case study in operational design failure rather than a lack of therapeutic potential.
The Operational Gap in Trial Design
According to analysis from Clinical Trial Vanguard, the HICKORY failure stems from a misalignment between the trial’s patient population and the sensitivity range of its primary endpoint. In rare metabolic diseases like HPP, patient heterogeneity—variations in age, disease severity, and baseline ambulatory function—can create wide disparities in how patients perform on functional tests like the 6MWT. If the enrolled study population includes too many individuals whose baseline performance is already either too high or too low, the drug’s effect may be masked, rendering the trial statistically underpowered regardless of its clinical potential.
Procedural Shifts for Future Trials
The core issue highlighted by the HICKORY program is the traditional feasibility process, which typically focuses on site readiness—such as patient numbers and equipment availability—rather than validating whether the enrolled population fits the statistical sensitivity window. Experts suggest that clinical operations leads must now integrate an “enrichment review” into the pre-activation phase. This involves creating a population characterization document that translates power calculation assumptions into plain-language baseline eligibility guidance. By identifying which patient profiles are likely to produce a readable signal, sponsors can avoid enrolling cohorts that are statistically incompatible with the trial design. For sites, this necessitates a shift in posture: asking for statistical sensitivity parameters during the feasibility stage to ensure that the patient registry truly aligns with the trial’s measurable goals.